Industry Veterans Join Stereotaxis Commercial Leadership Team as Company Advances Robust Innovation Pipeline
August 02 2022 - 9:06AM
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical
robotics for minimally invasive endovascular intervention, today
announced the significant enhancement of its commercial leadership
team with the successful recruitment of two veterans of the medical
device, surgical robotics and electrophysiology fields.
Joining Stereotaxis are experienced commercial
leaders with relevant and complementary expertise:
- Frank Van Hyfte is joining as Vice
President of Europe, the Middle East and Africa. Mr. Van Hyfte
spent over 15 years at Intuitive Surgical, the global leader in
robotic surgery, between 2000 and 2016. While at Intuitive Surgical
he rose in responsibility from the role of a Clinical Specialist to
Director of Direct and Indirect Markets in Europe, the Middle East,
India and Africa. He subsequently served in senior commercial
leadership roles at Exact Imaging, EDAP TMS, and eCential
Robotics.
- Tim Glynn is joining as Vice
President, Market Development. Mr. Glynn most recently served as
Vice President of Business and Market Development at Acutus
Medical, an innovator in the electrophysiology mapping and ablation
field. His responsibilities evolved from establishing commercial
beachheads in Europe and the United States to managing product
marketing, physician relationships and business partnerships. Prior
to Acutus Medical, he served in senior marketing roles at Volcano
Corporation, a leader in intravascular imaging for coronary and
peripheral interventions.
“We see in Stereotaxis the opportunity to build
a preeminent robotic surgery company that positively transforms
electrophysiology specifically and endovascular surgery more
broadly,” said Mr. Van Hyfte and Mr. Glynn in a joint statement.
“We join Stereotaxis at a fitting time as it establishes the
product ecosystem that can allow for substantial commercial growth.
We look forward to working together with the existing Stereotaxis
team in building a highly impactful commercial organization.”
The expertise of these new commercial leaders
will complement Stereotaxis’ existing commercial leadership:
Michael Tropea, Vice President of North America, and Casey Payne,
Vice President of Asia Pacific. Mr. Tropea leads Stereotaxis’
commercial teams in North America and has been instrumental in
establishing Stereotaxis’ capital sales processes, restarting
capital adoption, and managing various marketing and business
development initiatives. Mr. Payne leads Stereotaxis’ Asia Pacific
and Global Training teams and has been central to the resurgence in
commercial adoption in Asia and advancement of Stereotaxis’
strategic collaborations in China.
“Stereotaxis has been energetically advancing a
robust innovation pipeline that enables significant adoption of
robotics across electrophysiology and endovascular surgery. In
preparation for these product launches, we are assembling the right
commercial leadership and establishing the commercial foundations
for significant growth,” said David Fischel, Chairman and CEO. “We
are excited to welcome Frank and Tim to the Stereotaxis team and
look forward to their contributions as leaders in our efforts to
pioneer endovascular robotics.”
About StereotaxisStereotaxis is
the global leader in innovative robotic technologies designed to
enhance the treatment of arrhythmias and perform endovascular
procedures. Its mission is the discovery, development and delivery
of robotic systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
expand access to minimally invasive therapy, and enhance the
productivity, connectivity, and intelligence in the operating room.
Stereotaxis technology has been used to treat over 100,000 patients
across the United States, Europe, Asia, and elsewhere. For more
information, please visit www.stereotaxis.com.
This press release includes statements that may
constitute "forward-looking" statements, usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially. Factors that would cause or contribute to such
differences include, but are not limited to, the Company's ability
to manage expenses at sustainable levels, acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its technology, competitive factors, changes resulting
from healthcare policy, dependence upon third-party vendors, timing
of regulatory approvals, the impact of pandemics or other
disasters, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments because some of these purchase orders and other
commitments are subject to contingencies that are outside of the
Company's control and may be revised, modified, delayed, or
canceled.
Investor Contacts: |
Media
Contact: |
David L. Fischel |
Bethanne Schluter |
Chairman and Chief Executive Officer |
Director, Marketing & Communications |
|
314-678-6213 |
Kimberly Peery |
B.Schluter@Stereotaxis.com |
Chief Financial Officer |
|
|
|
314-678-6100 |
|
Investors@Stereotaxis.com |
|
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Apr 2023 to Apr 2024